OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing.   The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital.  Founded in March 2025, Shanghai-based OTR Therapeutics aims to discover and acquire distinctive assets in preclinical and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!